Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01703923 | An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough | PHASE2 | COMPLETED | 83 | — | — | Nov 1, 2012 | Sep 1, 2013 | Nov 5, 2014 | 8 | United States |
Change in start-to-end difference in cough count, active vs. placebo treatment periods
| Arm | Type | Description |
|---|---|---|
| FP01 6mg or Placebo | EXPERIMENTAL | FP01 6mg Oral |
| FP01 12mg or Placebo | EXPERIMENTAL | FP01 12mg Oral |
| Name | Type | Description |
|---|---|---|
| FP01 | DRUG | - |
| placebo | DRUG | - |
Inclusion Criteria: * Subject must sign an Institutional Review Board approved informed consent and agree to complete required clinic visits * Subjects must be able to read and write English * Subject must exceed a cough severity threshold (VAS) during screening visit (Cough Severity VAS Score ≥ 35...